Smith & Nephew (BSP:S1NN34) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:S1NN34 Smith & Nephew PLC BSP:S1NN34
20 GF Score
Price R$30.30
GF Value R$33.59
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Smith & Nephew SpecialCharges?

Special Charges only applies to banks.

BSP:S1NN34
20GF Score
Smith & Nephew PLC BSP:S1NN34
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Smith & Nephew (BSP:S1NN34) Overvalued in 2026?

Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued. The current stock price of R$30.30 is trading 9.8% below its estimated GF Value™ of R$33.59. GuruFocus considers Smith & Nephew to be Modestly Undervalued.

Key valuation signals for BSP:S1NN34:

  • SpecialCharges:
  • GF Value™: R$33.59 vs. price of R$30.30 (9.8% below fair value)
  • GF Score™: 20/100 with 2 warning signs

No single metric tells the full story. See the BSP:S1NN34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Smith & Nephew Business Description

Address Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, GBR, WD18 8YE
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
20GF Score

Get the complete analysis for BSP:S1NN34

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$30.30
Price
R$33.59
GF Value